Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Prospective, Open Label, Two Period, Fixed Sequence, Dose-Escalation Study of the PK and Safety of BAX 826 (PSA-rFVIII) in Previously Treated Patients With Severe (FVIII <1%) Hemophilia A

NCT02716194 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT02716194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02716194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Prospective, Open Label, Two Period, Fixed Sequence, Dose-Escalation Study of the PK and Safety of BAX 826 (PSA-rFVIII) in Previously Treated Patients With Severe (FVIII <1%) Hemophilia A
Lead sponsor
Baxalta now part of Shire
Phase
Phase 1
Overall status
Completed
Start date
March 3, 2016
Completion date
January 17, 2017
Enrollment
40 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a